Abraxis and ProMetic target US biopharma market
Abraxis has licensed rights to use ProMetic’s protein technology in the development of four new biopharmaceuticals that it hopes will generate around $600m (€422.5m) in US sales.
Archives for September 8, 2008
Contract manufacturing: News in brief
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.